Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

UKONS 2016 | The importance of clinical nurse specialists in providing supportive care for Radium-223 treatment

Louise Causer • 10 Nov 2016
UKONS 2016
Prostate Cancer

Louise Causer, clinical nurse specialist, The Royal Marsden NHS Foundation Trust, London, UK discusses the importance of clinical specialist nurses in providing supportive care for men undergoing Radium-223 treatment for prostate cancer. Her association with Radium-223 started in 2004 when was asked to get involved in the studies administering Radium-223. But with background in oncology, she sort out other clinical nurse specialists involved with patients with prostate cancer. This is very important as prostate cancer is a long term condition, and it is difficult for nurses involved in the technical aspects of administering Radium-223 to provide the support needed to deal with the large number of problems and challenges prostate cancer patients face. She explains how Radium-223 treatment fits very nicely in a the type of pathway one sees one sees with chemotherapy, where multidisciplinary pre-assessment takes place. Recorded at the 2016 Annual Meeting of the Oncology Nursing Society (ONS), held in Brighton, UK.

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals